Alumis to Present at the Jefferies Global Healthcare Investor Conference. SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company ...

Alumis' lead drug, ESK-001, is a potential best-in-class TYK2 inhibitor for treating plaque psoriasis and immunological diseases in general., with phase 3 trial data expected in 1H2026. With ...

Alumis's lead product candidate, ESK-001, has shown promising results in a Phase 2 psoriasis study and is expected to generate multi-billion dollar revenues if approved.

Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS stock is a sell.

Alumis Inc. – Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy ...

June 28 (Reuters) - Shares of biopharmaceutical firm Alumis (ALMS.O), opens new tab opened nearly 16% below their initial public offering (IPO) price in their debut on the Nasdaq on Friday. A long ...

--Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with ...

Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases. Beyond TYK2, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today announced that ...

Alumis has reeled in an eye-watering $259 million series C, financing that will help launch a phase 3 psoriasis trial for lead asset ESK-001.

SOUTH SAN FRANCISCO, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (“Alumis” or the “Company”) (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies ...